AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika B tler, Dr. oec., to its Board of Directors Dr. Shaw is a pharmaceutical industry expert who has been invol

AC Immune Holds its Extraordinary General Meeting

and Appoints Monica Shaw, M.D., and Prof. Monika B tler, Dr. oec., to its Board of Directors

Dr. Shaw is a pharmaceutical industry expert

who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization

Prof. B tler is a leading Swiss economist

and former Vice President of the independent Swiss Covid-19 Science Taskforce

Lausanne, Switzerland,

October 29, 2021 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for

neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D.,

and Prof. Monika B tler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. B tler

replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.

Douglas Williams, Ph.D., Chairman of the Board

of Directors of AC Immune, commented: "Dr. Shaw and Prof. B tler are accomplished industry leaders with complementary

skill sets and we are delighted to welcome them to the Board. Dr. Shaw's extensive executive and drug development experience, together

with Prof. B tler's deep expertise in finance and economics, will be invaluable as we work to revolutionize the diagnosis and

treatment of Alzheimer's and other neurodegenerative diseases. We are eager to begin working with them and look forward to benefiting

from their strategic insights. We also extend our sincere thanks to Mr. Velasco and Dr. Bollmann, as their contributions as Directors

helped to establish AC Immune's position as an industry leader."

Dr. Shaw commented: "Joining AC Immune's

Board is a truly exciting opportunity. The Company is at the forefront of its field with a unique precision medicine approach that properly

recognizes the complexity of neurodegenerative disease as well as the importance of earlier intervention. I look forward to working with

my fellow Directors to provide valuable insights and guidance as the Company advances its industry-leading strategy."

Prof. B tler commented: "It is

an honor to join AC Immune's Board. The Company has an impressive track record of establishing partnerships with industry leaders

to achieve an optimal risk-benefit balance for creating shareholder value while growing its pipeline. It also has a strong balance sheet

and the backing of a high-quality investor syndicate, which I believe leaves the Company poised for sustained success."

Prior to the meeting, the Board withdrew agenda

items 2.1, 2.2 and 2.3.

The meeting was held in accordance with the requirements

of the Covid-19 Ordinance 3, issued by the Swiss Federal Council.

Monica Shaw, M.D., is a pharmaceutical

industry expert who has held senior leadership positions and was involved in advancing more than 15 therapeutic products from first-in-human

studies through regulatory approvals and commercialization across multiple geographies. She also played key business development roles

in company acquisition and integration and co-development partnerships. Through her work, Dr. Shaw gained extensive specialty experience

in the fields of dermatology, immuno-inflammation, HIV, neurology, and oncology.

Currently, Dr. Shaw is Executive Vice President

Head Region Europe, Canada, Australia, for Leo Pharma. She has previously held broad leadership roles at other leading pharmaceutical

companies, including as Vice President Commercial Head Asia Pacific region at GSK/ViiV Healthcare, and Medical Director and Chief Scientific

Officer UK for Novartis, in addition to previous leadership positions at Norgine, Shire and Merck KGaA.

Dr. Shaw holds an M.D. from the University of Oxford

Medical School and is a Member of the Royal College of Physicians.

Prof. Monika B tler, Dr. oec.,

is a leading Swiss economist and former Vice President of the independent Swiss Covid-19 Science Taskforce. She is a member of the Board

of Directors and the audit committees of both Schindler Holding AG and Huber & Suhner AG. Prof. B tler is also a member of the

Swiss National Bank's Council, where she serves on the remuneration committee. Her international economic expertise is in public

policy and managerial economics, including an advisory role to the World Bank and work in the U.S. and Europe. Prof. B tler is a

Vice President of the Foundation Board of the Gebert R f Foundation, a science and innovation foundation that supports entrepreneurial

projects which are committed to achieving an impact.

Prof. B tler holds a Doctorate in Economics

from the University of St. Gallen, a Doctorate Honoris Causa from the University of Lausanne, and a Diploma in Mathematics/Physics from

the University of Zurich.

AC Immune SA is clinical-stage biopharmaceutical

company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease,

Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology

platforms, SupraAntigen and Morphomer , fuel its broad and diversified pipeline of first- and best-in-class

assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC

Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies

including Genentech, a member of the Roche

Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary

programs and >$3 billion in potential milestone payments.

SupraAntigen is a registered

trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer is a registered

trademark of AC Immune SA in CN, CH, GB, JP, and NO.

For further information, please contact:

Forward looking statements

This press release contains statements that constitute

"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future

operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements

by forward-looking words such as "may," "might," "will," "should," "expects,"

"plans," "anticipates," "believes," "estimates," "predicts," "projects,"

"potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements

are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual

results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties

include those described under the captions "Item 3. Key Information - Risk Factors" and "Item 5. Operating and

Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange

Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19.

Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update

them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking

statements are qualified in their entirety by this cautionary statement.